Identification and preparation method of antibacterial peptide Attacin resisting streptococcus agalactiae

By identifying and expressing the antibacterial peptide Attacin from the peach borer and expressing in E.coli BL21, the problem of Streptococcus alactis adipose resistance is solved, and high-purity and low-cost antibacterial effect is achieved, making Streptococcus adipose. treatment provides potential alternatives.

CN119060152APending Publication Date: 2024-12-03ANYANG INST OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411261330.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-12-03

Smart Images

  • Figure CN119060152A_ABST
    Figure CN119060152A_ABST
Patent Text Reader

Abstract

The invention discloses identification of an antibacterial peptide Attacin resisting streptococcus agalactiae and a preparation method of the antibacterial peptide Attacin. Through bioinformatics analysis, an open reading frame sequence of new Attacin is obtained from a dichocrocis punctiferalis transcriptome database, after an amino acid sequence is derived, a signal peptide sequence of the new Attacin is predicted, a gene sequence corresponding to polypeptide with the signal peptide sequence removed is synthesized, prokaryotic expression plasmids are constructed for in-vitro escherichia coli expression, and the new Attacin is obtained. The expressed and purified Attacin has a good antibacterial effect on streptococcus agalactiae. The Attacin disclosed by the invention is a newly identified antibacterial peptide, and the Attacin prepared by in-vitro expression has good antibacterial activity on streptococcus agalactiae, so that a potential application value of the Attacin in prevention and control of streptococcus agalactiae in animal husbandry, aquaculture and food processing is provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the identification of an antimicrobial peptide Attacin against Streptococcus agalactiae and a preparation method thereof, in particular to a new antimicrobial peptide Attacin from Concha oleracea, and also to a prokaryotic expression preparation method of the Attacin and its antimicrobial activity against Streptococcus agalactiae. The present invention belongs to the technical field of antimicrobial drug development. Background Art

[0002] In recent years, with the irregular application of a large number of antibiotics in clinical practice, some drug-resistant strains have continued to emerge, seriously threatening animal husbandry and aquaculture, human health and public health safety. Therefore, the development of new antimicrobial drugs has received widespread attention. Antimicrobial peptides, as a class of polypeptide molecules composed of amino acids, have the advantages of few side effects and are not easy to produce bacterial resistance. The insect-derived antimicrobial peptides reported so far are mainly divided into cecropin antimicrobial peptides, defensin antimicrobial peptides, geranosin antimicrobial peptides, and aggressin antimicrobial peptides. These antimicrobial peptides act as host defense factors to resist the invasion of foreign pathogenic microorganisms and play an immune role to protect the host.

[0003] Commonly used methods for identifying antimicrobial peptides include separation and purification, bioinformatics analysis, artificial design and synthesis, etc. With the continuous development of modern bioinformatics software and high-throughput sequencing technology, the efficiency of identifying new antimicrobial peptides by combining the two has been continuously improved, and this method is gradually becoming the main method for identifying antimicrobial peptides. Discovering a new antimicrobial peptide sequence is only the first step. Whether the antimicrobial peptide has antimicrobial activity needs further verification, and antimicrobial peptide materials need to be obtained before the verification effect. At present, the acquisition of antimicrobial peptides mainly includes extraction and purification from in vivo biological materials, in vitro chemical synthesis, prokaryotic and eukaryotic expression preparation, etc. Extraction and purification are usually time-consuming and labor-intensive, and the purity is limited, and the antibacterial effect is often reduced during the extraction and purification process. In vitro chemical synthesis is usually costly, and the cost is acceptable in the laboratory research stage. If pilot and clinical applications are carried out, in vitro expression preparation is an indispensable method.

[0004] Streptococcus agalactiae is an important zoonotic bacterium that is widely prevalent in animal husbandry and aquaculture. It was first discovered in dairy cows with mastitis, and later found in pregnant women and newborns in various countries. The bacteria mainly cause sepsis and meningitis in animals, with a high mortality rate. The long-term use of antibiotics in the clinical treatment of Streptococcus agalactiae has also led to the emergence of some drug-resistant strains. Therefore, there is an urgent need to develop new antibacterial drugs. Summary of the invention

[0005] In view of the problems existing in the prior art, the purpose of the present invention is to provide a new antimicrobial peptide Attacin, including its open reading frame sequence, prokaryotic expression preparation method, and the prepared Attacin has good antimicrobial activity.

[0006] The technical solution adopted by the present invention is: An antimicrobial peptide Attacin for resisting Streptococcus agalactiae, the open reading frame sequence of the antimicrobial peptide is SEQ ID No.1: ; The amino acid sequence of the antimicrobial peptide is SEQ ID No.2: MFAVCVALGFMLIGVNSQAASSISVKSDGTSTFGAKIPIAGNDQAKLSAFASIAQPSGDITKGLSLDTARGHGLSIAHGTASFGEQLTGAGRLNILDSGNHKLDANAFITKNMPTKFPGVSDFNTVGGNLDYMFKDRIGASIGAARTPFLDRTDLNAMGKLNIFRNPTTSIDFNAGLQRTITPQFSQTQPFTGFSLTKFFKK*; The polypeptide sequence of the antimicrobial peptide after removing the signal peptide is SEQ ID No.3: QAASSISVKSDGTSTFGAKIPIAGNDQAKLSAFASIAQPSGDITKGLSLDTARGHGLSIAHGTASFGEQLTGAGRLNILDSGNHKLDANAFITKNMPTKFPGVSDFNTVGGNLDYMFKDRIGASIGAARTPFLDRTDLNAMGKLNIFRNPTTSIDFNAGLQRTITPQFSQTQPFTGFSLTKFFKK.

[0007] A method for preparing an antimicrobial peptide Attacin against Streptococcus agalactiae, synthesizing the above open reading frame gene sequence, adding restriction sites to obtain an optimized sequence SEQ ID No.4, and constructing the gene sequence into a prokaryotic expression vector plasmid pET-28a(+) by an enzyme cutting method; The optimized sequence is SEQ ID No.4:.

[0008] Further, the constructed prokaryotic expression vector was transformed into E. coliThe target protein Attacin was successfully expressed in BL21(DE3), and the inclusion body was purified with a purity of 90%.

[0009] Furthermore, the expressed and purified Attacin had a good antibacterial effect against Streptococcus agalactiae, with a minimum inhibitory concentration (MIC) of 18.8 µg / mL.

[0010] Beneficial effects: This patent identifies the novel antimicrobial peptide Attacin for the first time and provides a novel antimicrobial peptide Attacin and its open reading frame sequence; This patent discloses the prokaryotic expression preparation method of the new Attacin, which has the advantages of large preparation volume, high purity, and low price, laying the foundation for the future industrial production and clinical application of Attacin; Attacin discovered in this patent exhibits good antibacterial effect against Streptococcus agalactiae, and is expected to reduce or replace antibiotics in the treatment of Streptococcus agalactiae disease in the future. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 It is the open reading frame sequence and amino acid sequence of the new Attacin; the blue background is the signal peptide sequence.

[0012] Figure 2 The figure shows the prokaryotic expression and purification of the polypeptide gene sequence of the new Attacin after removing the signal peptide sequence; Figure A shows the induced expression and solubility analysis of the fusion protein, where M, 1, 2, 3, and 4 represent protein Marker, uninduced, IPTG induced, supernatant expression, and inclusion body expression, respectively; Figure B shows the purification of the fusion protein, where M, 1, and 2 represent protein Marker, 0.5 mg / mL BSA control sample, and purified fusion protein, respectively.

[0013] Figure 3 This is the detection of MIC of the expressed and purified new Attacin against Streptococcus agalactiae; Figure A is the resazurin indicator method, and Figure B is the OD value measurement method.

[0014] Figure 4 This is the effect of the expressed and purified new Attacin on the leakage of intracellular nucleic acids and proteins in Streptococcus agalactiae; Figure A is the nucleic acid leakage detection, and Figure B is the protein leakage detection.

[0015] Figure 5 To study the effect of the expressed and purified new Attacin on the intracellular ROS content of Streptococcus agalactiae. DETAILED DESCRIPTION

[0016] The present invention will be described in detail below in detail with reference to the accompanying drawings.

[0017] The main raw materials in the following examples are: Attacin was expressed in prokaryotes and purified by nickel column affinity chromatography. Bacterial standard strains were purchased from the company and amplified and preserved in this laboratory. Other reagents and materials such as resazurin can be obtained from commercial sources. The experimental methods described are all conventional experimental methods unless otherwise specified.

[0018] The identification and preparation method of the anti-Streptococcus agalactiae Attacin of the present invention are specifically implemented as follows: 1.1 Discovery of new Attacin The Attacin disclosed by the present invention is a novel antimicrobial peptide derived from Concha oleracea, and is obtained by the following method: using the transcriptome of Concha oleracea as a database, according to the identified Attacin sequence, an open reading frame sequence of the novel Attacin disclosed by the present invention is found by TBtools comparison, its amino acid sequence is deduced, and its signal peptide sequence is predicted by online software.

[0019] The novel Attacin provided by the present invention is derived from Concha serrata. The bioinformatics comparison and signal peptide prediction analysis of the transcriptome sequencing database of Concha serrata are as follows: Figure 1 As shown, the antimicrobial peptide Attacin open reading frame (ORF) contains a 609 bp nucleotide sequence (SEQ ID No. 1), encoding 202 amino acid residues (SEQ ID No. 2), and the polypeptide after removing the signal peptide is 185 amino acid residues (SEQ ID No. 3).

[0020] 1.2 Preparation of new antimicrobial peptides The polypeptide gene sequence of the identified new Attacin after removing the signal peptide was codon optimized to synthesize a 570bp optimized sequence (SEQ ID No. 4) with added restriction sites. The gene sequence was directionally cloned into the pET-28a(+) vector by double restriction digestion. The positive plasmid with correct sequencing was transformed into E. coli In BL21, the expression was induced by IPTG and optimized to the best expression conditions to achieve the prokaryotic expression of Attacin. The induced expression bacteria were ultrasonically broken and centrifuged, and the supernatant and precipitate were prepared for SDS-PAGE analysis. It was found that Attacin was present in both the supernatant and the precipitate, and more was present in the precipitate. E. coli After sonication, the inclusion bodies were treated and then nickel column affinity chromatography was performed to purify the fusion protein with the His tag. The eluted sample was analyzed by SDS-PAGE, and it was found that the Attacin was successfully purified. Quantitative analysis of the purified protein showed that the purity of the expressed Attacin was as high as 90%.

[0021] The results are as follows Figure 2 As shown, SDS-PAGE analysis showed that the polypeptide gene after removing the signal peptide sequence of Attacin was E. coli The expression was successfully achieved in BL21, and the expression was found in both the supernatant and the precipitate, but the expression level in the precipitate was higher. After a large amount of induction, the Attacin was ultrasonically broken and obtained by nickel column affinity chromatography. The SDS-PAGE analysis results showed that the Attacin was successfully expressed and purified.

[0022] 1.3 Determination of minimum inhibitory concentration (MIC) A 300 µg / mL Attacin solution was prepared with sterile PBS solution, and Attacin was diluted in a 96-well plate by serial dilution method, with 50 µL per well. Streptococcus agalactiae cultured to the logarithmic growth phase was diluted to 2× 10 5 CFU / mL. Take 50 µL of the diluted bacterial solution and add it to the wells containing different concentrations of Attacin. Set up 3 replicate wells for each Attacin concentration, and set up PBS solution + bacterial solution as a negative control, and kanamycin + bacterial solution as a positive control. Incubate in a 37℃ incubator for 14 h, measure the OD value, then add 10 µL of 6 mmol / L resazurin solution to each well, continue to incubate in a 37℃ incubator for 3 h, observe the color changes in the wells and take pictures.

[0023] The results are as follows Figure 3 As shown, the antibacterial activity of Attacin against Streptococcus agalactiae was detected by the doubling dilution method and resazurin indicator. The results showed that the MIC of Attacin against Streptococcus agalactiae was 18.8 µg / mL.

[0024] 1.4 Detection of nucleic acid and protein leakage The Streptococcus agalactiae cultured to the logarithmic growth phase was centrifuged at room temperature at 4000 r / min for 5 min, and the bacterial precipitate was collected. It was washed twice with sterile PBS, resuspended and divided into 5 groups, and Attacin was added to the final concentrations of 0, 1 / 2, 1 and 2 MIC, respectively, and 0.3% Triton X-100 solution was used as a positive control. It was placed in a 37℃ preheated electric thermostatic water bath and incubated for 1 h. Then it was centrifuged at 4℃ and 12000 r / min for 2 min, and the absorbance of the supernatant at 260 nm and 280 nm was detected by ultra-micro spectrophotometer.

[0025] The results are as follows Figure 4As shown, the effect of Attacin on the leakage of intracellular nucleic acids and proteins of Streptococcus agalactiae was detected by ultramicrospectrophotometer. The results showed that treating Streptococcus agalactiae with 2 MIC of Attacin for 1 h could significantly increase the leakage of nucleic acids and proteins in the extracellular supernatant.

[0026] 1.5 Detection of Reactive Oxygen Species (ROS) S. agalactiae cultured to the logarithmic growth phase were collected and washed twice with sterile PBS. DCFH-DA was added to the cells after resuspending to a final concentration of 10 µmol / L. The cells were incubated in a 37°C electric thermostatic water bath for 20 min, and mixed by inversion every 3 min. The cells were then washed 3 times with sterile PBS to fully remove the unloaded DCFH-DA. The cells were resuspended and divided into 5 groups. Attacin was added to the cells to a final concentration of 0, 1 / 2, 1, and 2 MIC, respectively, and Rosup was used as a positive control. The cells were incubated in a 37°C electric thermostatic water bath, and the fluorescence intensity at an excitation wavelength of 488 nm and an emission wavelength of 525 nm was detected using a multifunctional microplate reader at 30 min and 60 min, respectively.

[0027] like Figure 5 As shown, the effect of Attacin on the accumulation of intracellular ROS in Streptococcus agalactiae was detected by a reactive oxygen species (ROS) detection kit. The results showed that treatment of Streptococcus agalactiae with 1 MIC of Attacin for 30 min could significantly increase the accumulation of intracellular ROS in Streptococcus agalactiae.

[0028] In summary, this patent identified a new antimicrobial peptide Attacin and prepared it through prokaryotic expression. By testing MIC, it was found that Attacin prepared by prokaryotic expression had a good antibacterial effect on Streptococcus agalactiae. This patent not only discloses a new antimicrobial peptide, but also provides a method for its in vitro expression and preparation, laying the foundation for its industrial production and clinical application, providing a potential antibiotic alternative for the prevention and treatment of Streptococcus agalactiae, and providing potential application value for Attacin in the prevention and control of Streptococcus agalactiae in animal husbandry, aquaculture, and food processing.

Claims

1. An antimicrobial peptide Attacin, characterized in that: The amino acid sequence of the antimicrobial peptide Attacin is SEQ ID No. 2; The polypeptide sequence of the antimicrobial peptide Attacin after removing the signal peptide is SEQ ID No.

3.

2. The antimicrobial peptide Attacin according to claim 1, characterized in that: The gene sequence encoding the antimicrobial peptide Attacin is SEQ ID No.

1.

3. A method for preparing an antimicrobial peptide Attacin, characterized in that: The gene sequence as claimed in claim 2 was synthesized, and the gene sequence was constructed into the prokaryotic expression vector plasmid pET-28a(+) by enzyme digestion.

4. The method for preparing the antimicrobial peptide Attacin according to claim 3, characterized in that: The constructed prokaryotic expression vector was transformed into E. coli BL21(DE3) and was successfully expressed, and the target protein in the inclusion body could be purified with a purity of 90%.

5. The use of the antimicrobial peptide Attacin as claimed in claim 4 in the treatment of Streptococcus agalactiae, wherein the minimum inhibitory concentration (MIC) is 18.8 µg / mL.